Letter from Singapore: The clinical and research response to COVID‐19

Sanjay H Chotirmall,Lin-Fa Wang,John A Abisheganaden,Sanjay H. Chotirmall,Lin‐Fa Wang,John A. Abisheganaden
DOI: https://doi.org/10.1111/resp.13929
IF: 6.9
2020-08-17
Respirology
Abstract:Singapore is a city‐state within Southeast Asia with a multi‐ethnic population. With high levels of travel and economic connectivity to the world, it was a key location of the 2003 severe acute respiratory syndrome coronavirus (SARS‐CoV) outbreak: a memory that significantly influenced the clinical and research response to SARS‐CoV‐2. Singapore was one of the first countries outside China to identify, document and diagnose SARS‐CoV‐2 infections including local transmission.<span><a class="bibLink tab-link" href="#resp13929-bib-0001">1</a>, <a class="bibLink tab-link" href="#resp13929-bib-0002">2</a></span> The first case was confirmed on 23 January and by 4 February 2020, local transmission was reported. As of 27 July 2020, 50 838 cases are reported with 27 fatalities illustrating a favourable case fatality rate compared to other jurisdictions.
respiratory system
What problem does this paper attempt to address?